All In Biotech

Drug Trial Radar · NCT04976088

Clinical Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs

Randomized, Double Blind, Parallel-groups, Non-inferiority Versus Flector® and Superiority Versus Placebo, Phase III Clinical Trial With Diclofenac Sodium 140 mg Medicated Plaster in Patients With Impact Injuries of the Limbs

Last checked: Nov 20, 2026Latest source record: Oct 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 214 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

214

Actual

Start

May 25, 2018

Primary completion

Oct 27, 2018

Study completion Oct 27, 2018

Sponsor

Lead sponsor
Fidia Farmaceutici s.p.a.Industry
Sponsor type
Industry
First posted
Jul 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III, multinational, multicentre, randomized, prospective, double blind, parallel groups, placebo-controlled study to evaluate the analgesic effects of Test Diclofenac Sodium 140mg medicated plaster, Reference DIEP 180 mg medicated plaster, Flector® and Placebo plaster in patients with painful and phlogistic disease due to acute traumatic events of the limbs.

Conditions

  • Trauma Injury
  • Inflammation

Interventions

  • Diclofenac Sodium 140 mg medicated plasterDrug

    Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day

  • Diclofenac epolamine (DIEP) 180mg medicated plaster, FlectorDrug

    Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day

  • PlaceboDrug

    Placebo: Placebo plaster, topical application once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in VAS score (Visual Analogue Scale from 0 to 100 mm, where the left extreme means "No pain = 0" while the right extreme means "Worst Pain Imaginable = 100") for pain at rest at 72 ± 2 hours (Day 4) after treatment start.Time frame: 72 hours

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Praxis Dr. med. Helmut Pabst

    Gilching, Germany

  • Praxis Dr. Jürgen Ulrich Schaale-Maas

    Rheinbach, Germany

  • Synexus Budapest DRC

    Budapest, Hungary

  • Magyar Honvédség, Egészségügyi Központ Baleseti Sebészeti Osztály

    Budapest, Hungary

  • Uzsoki utcai Kórház Ortopéd-traumatológiai Osztály

    Budapest, Hungary

  • Synexus Debrecen AS

    Debrecen, Hungary

  • Platán Egészségcentrum

    Eger, Hungary

  • Synexus Magyarország kft. Gyula DRS

    Gyula, Hungary

  • Shawfar-med Kft

    Kalocsa, Hungary

  • Jutrix Kft.

    Kecskemét, Hungary

  • Bács-Kiskun Megyei Kórház Kiskunfélegyházi Városi Kórház és Rendelőintézet

    Kiskunfélegyháza, Hungary

  • G&V Pharma-Med Bt.

    Makó, Hungary

  • Nagyatádi Kórház Reumatológiai Osztály

    Nagyatád, Hungary

  • Synexus Magyarország EÜ szolg Kft.

    Zalaegerszeg, Hungary

  • Ambulatorio MMG dott. Andrea Pedemonte

    Genova, Italy

  • Ambulatorio MMG dott. Paolo Picco

    Sant'Olcese Chiesa, Genova, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.